COVID-19 rapid evidence summary: Tocilizumab for COVID-19 [ES33] NICE (published 15th January 2021)
Unpublished preliminary evidence from the REMAP ‑CAP study has suggested that tocilizumab is beneficial in adults with severe COVID‑19 who are critically ill and receiving respiratory or cardiovascular organ support in an intensive care setting (all randomised within 24 hours of starting organ support). (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - January 15, 2021 Category: Consumer Health News Source Type: news

Arthritis drugs effective in improving survival in sickest COVID-19 patients, NIHR
Results from the REMAP-CAP clinical trial evaluated the effect of treatments on a combination of survival and length of time patients need support in an intensive care unit (ICU). Patients receiving tocilizumab and a second drug called sarilumab - both types of immune modulators - have a significant impact on patient survival and can reduce the relative risk of death by 24% when administered to patients within 24 hours of entering intensive care. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - January 14, 2021 Category: Consumer Health News Source Type: news

UK Approves Arthritis Drugs for Critically Ill COVID-19 Patients
The immunosuppressive drugs tocilizumab and sarilumab improved survival and recovery time of intensive care COVID-19 patients, according to a preprint. (Source: The Scientist)
Source: The Scientist - January 11, 2021 Category: Science Tags: News & Opinion Source Type: news

Interim Position Statement: Interleukin-6 inhibitors (tocilizumab or sarilumab) for patients admitted to ICU with COVID-19 pneumonia (adults), MHRA (issued 8th January 2021)
The REMAP-CAP platform trial has reported survival and time to recovery benefits for tocilizumab or sarilumab. Clinicians should consider prescribing IV tocilizumab (sarilumab an alternative if available) following the criteria defined in this interim position statement. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - January 11, 2021 Category: Consumer Health News Source Type: news

Covid Deaths Lowered in Trial of Tocilizumab and Sarilumab
The big dip in mortality shown in the trial of about 800 patients has caught some experts by surprise because previous studies of the drugs showed little benefit. (Source: NYT Health)
Source: NYT Health - January 8, 2021 Category: Consumer Health News Authors: Katherine J. Wu Tags: Clinical Trials Coronavirus (2019-nCoV) Drugs (Pharmaceuticals) medRxiv Dexamethasone (Drug) Research Immune System Deaths (Fatalities) your-feed-healthcare Source Type: news

Roche, Sanofi Arthritis Drugs Reduce Death Rates Among Sickest COVID-19 Patients   Roche, Sanofi Arthritis Drugs Reduce Death Rates Among Sickest COVID-19 Patients  
Treating critically ill COVID-19 patients with Roche's Actemra or Sanofi's Kevzara arthritis drugs significantly improves survival rates and reduces the amount of time patients need intensive care, study results showed on Thursday.Reuters Health Information (Source: Medscape Orthopaedics Headlines)
Source: Medscape Orthopaedics Headlines - January 8, 2021 Category: Orthopaedics Tags: Infectious Diseases News Source Type: news

New Covid drugs ‘significantly’ reduce mortality in critically ill, study finds
Tocilizumab and sarilumab both shown to improve chances of survival and recovery in patients admitted to intensive care (Source: Reuters: Health)
Source: Reuters: Health - January 8, 2021 Category: Consumer Health News Source Type: news

Covid UK: Arthritis drugs that cut ICU death risk 24% available now
The PM said the anti-inflammatory drugs tocilizumab and sarilumab would be made available across the UK with immediate effect, 'potentially saving thousands of lives'. (Source: the Mail online | Health)
Source: the Mail online | Health - January 7, 2021 Category: Consumer Health News Source Type: news

Arthritis drugs found to reduce risk of death in severe Covid-19 cases
Immunosuppressants tocilizumab and sarilumab also reduce stays in intensive care by at least seven days on average (Source: FT.com - Drugs and Healthcare)
Source: FT.com - Drugs and Healthcare - January 7, 2021 Category: Pharmaceuticals Source Type: news

Arthritis drugs could help save lives of Covid patients, research finds
Results suggest tocilizumab and sarilumab could cut relative risk of death of those in intensive care by 24%Coronavirus – latest updatesSee all our coronavirus coverageTwo drugs used to treat rheumatoid arthritis could help to save the lives of one in 12 intensive care patients with severe Covid, researchers have found.The NHS will begin using tocilizumab to treat coronavirus patients from Friday, health officials said after results from about 800 patients confirmed the drug brings benefits, potentially cutting the relative risk of death by 24%.Continue reading... (Source: Guardian Unlimited Science)
Source: Guardian Unlimited Science - January 7, 2021 Category: Science Authors: Nicola Davis Science correspondent Tags: Coronavirus UK news Medical research Infectious diseases Source Type: news

Position statement: Use of investigational immunomodulatory medicines for COVID-19 Interim support for UK hospital clinicians, RCP
Key messages • A subset of patients with COVID-19 may experience an exaggerated hyperinflammatory response • COVID-19 associated hyperinflammation predominantly involves the lung however may progress to secondary haemophagocytic lymphohistocytosis (sHLH) which is a systemic and multi-organ condition with significant morbidity and mortality • CTAG strongly recommends systemic corticosteroids for patients who fit definitions of WHOdefined severe or critical COVID-19, or in patients who otherwise have a new oxygen requirement • CTAG also recommends not to use corticosteroid therapy in patients with...
Source: Current Awareness Service for Health (CASH) - December 21, 2020 Category: Consumer Health News Source Type: news

Drug treatments for covid-19: living systematic review and network meta-analysis (update), BMJ
Updated review includes results for new interventions (azithromycin, colchicine, interferons, rhG-CSF, tocilizumab) and evidence remdesivir may not reduce mortality or time to symptom resolution; glucocorticoids probably reduce length of ICU stay and increase ventilator-free days BMJ2020; 370 doi: 2 External 0 0 0 https://doi.org/10.1136/bmj.m2980 false https://doi.org/10.1136/bmj.m2980 true false%> (Published 30 July 2020). Cite this as: BMJ 2020;370:m2980. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - December 21, 2020 Category: Consumer Health News Source Type: news

Tocilizumab Reduces Odds of Ventilation or Death in Mostly Non-White COVID-19 Patients Tocilizumab Reduces Odds of Ventilation or Death in Mostly Non-White COVID-19 Patients
The interleukin-6 inhibitor tocilizumab reduced the combined likelihood of mechanical ventilation or death by 44% among mostly nonwhite patients hospitalized with COVID-19, according to a new international randomized test of 389 volunteers.Reuters Health Information (Source: Medscape Critical Care Headlines)
Source: Medscape Critical Care Headlines - December 18, 2020 Category: Intensive Care Tags: Infectious Diseases News Source Type: news

Tocilizumab Cuts Progression to Ventilation or Death in COVID - 19
But death from any cause by day 28 in those hospitalized with COVID - 19 pneumonia did not differ for tocilizumab versus placebo (Source: Pulmonary Medicine News - Doctors Lounge)
Source: Pulmonary Medicine News - Doctors Lounge - December 18, 2020 Category: Respiratory Medicine Tags: Infections, Nursing, Pharmacy, Pulmonology, Critical Care, Emergency Medicine, Journal, Source Type: news

Tocilizumab Cuts Progression to Ventilation or Death in COVID-19
FRIDAY, Dec. 18, 2020 -- Tocilizumab reduces the risk for progression to ventilation or death among hospitalized patients with COVID-19 pneumonia, according to a study published online Dec. 18 in the New England Journal of Medicine. Carlos Salama,... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - December 18, 2020 Category: Pharmaceuticals Source Type: news

Dec 4 2020 This Week in Cardiology Dec 4 2020 This Week in Cardiology
COVID vaccines, tocilizumab, finerenone, type 2 MI care, coronary CTA, and sotagliflozin are the topics discussed by John Mandrola, MD, in this week ’s podcast.theheart.org on Medscape (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - December 4, 2020 Category: Cardiology Tags: Cardiology Commentary Source Type: news

Could IL-6 Inhibition Benefit Patients With Severe COVID-19? Could IL-6 Inhibition Benefit Patients With Severe COVID-19?
Researchers behind a new observational study say they have found a'signal'of benefit for interleukin-6 inhibitors such as tocilizumab in reducing in-hospital mortality in COVID-19 patients.Reuters Health Information (Source: Medscape Critical Care Headlines)
Source: Medscape Critical Care Headlines - December 2, 2020 Category: Intensive Care Tags: Infectious Diseases News Source Type: news

Hemophagocytic Lymphohistiocytosis in a Patient With COVID-19 Hemophagocytic Lymphohistiocytosis in a Patient With COVID-19
This patient with hemophagocytic lymphohistiocytosis secondary to COVID-19 responded after one dose of the IL-6 receptor antagonist tocilizumab.Journal of Medical Case Reports (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 2, 2020 Category: Consumer Health News Tags: Family Medicine/Primary Care Journal Article Source Type: news

FDA approves Xolair ® (omalizumab) for adults with nasal polyps
             Basel, 01 December 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has approved the company ’s supplemental Biologics License Application (sBLA) for Xolair® (omalizumab) for the add-on maintenance treatment of nasal polyps in adult patients 18 years of age and older with inadequate response to nasal corticosteroids.1 Nasal polyps can lead to a loss of smell and nasal congestion, and frequently co-occur with other respiratory conditions, such as allergies and asthma. With this ap...
Source: Roche Investor Update - December 1, 2020 Category: Pharmaceuticals Source Type: news

FDA approves Xolair ® (omalizumab) for adults with nasal polyps
             Basel, 01 December 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has approved the company ’s supplemental Biologics License Application (sBLA) for Xolair® (omalizumab) for the add-on maintenance treatment of nasal polyps in adult patients 18 years of age and older with inadequate response to nasal corticosteroids.1 Nasal polyps can lead to a loss of smell and nasal congestion, and frequently co-occur with other respiratory conditions, such as allergies and asthma. With this ap...
Source: Roche Media News - December 1, 2020 Category: Pharmaceuticals Source Type: news

Tocilizumab for patients admitted to ICU with COVID-19 Pneumonia (Adults), NHS ENgland
Following early positive signals of benefit from the immune modulation therapy domain of the REMAP-CAP platform trial, a UK wide position statement has been agreed to support off-label prescribing and access to tocilizumab, administered intravenously, for eligible COVID positive patients in the intensive care setting. The interim position statement will be reviewed as further evidence becomes available, including from the REMAP-CAP trial. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - December 1, 2020 Category: Consumer Health News Source Type: news

Interim Position Statement: Tocilizumab for patients admitted to ICU with COVID-19 pneumonia (adults), Chief Medical Officer
Following data from the REMAP-CAP trial, this position statement provides information to clinicians and healthcare organisations considering prescribing tocilizumab for COVID-19 pneumonia when the internal governance arrangements are in place. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - November 26, 2020 Category: Consumer Health News Source Type: news

' Dramatic' Inflammation Reduction After OHCA With Tocilizumab'Dramatic' Inflammation Reduction After OHCA With Tocilizumab
A pilot study showed reduced systemic inflammatory response and cardiac injury in out-of-hospital cardiac arrest patients, with the hope of affecting mortality and neurologic outcome in larger trials.Medscape Medical News (Source: Medscape Critical Care Headlines)
Source: Medscape Critical Care Headlines - November 24, 2020 Category: Intensive Care Tags: Cardiology News Source Type: news

IDSA Updates COVID Guidelines for Antibodies, Antivirals, Others IDSA Updates COVID Guidelines for Antibodies, Antivirals, Others
Infectious disease experts critically review evidence for use of bamlanivimab, address new data on remdesivir and tocilizumab, and comment on new findings for the Oxford University COVID-19 vaccine.Medscape Medical News (Source: Medscape Pharmacist Headlines)
Source: Medscape Pharmacist Headlines - November 23, 2020 Category: Drugs & Pharmacology Tags: Infectious Diseases News Source Type: news

Roche's Actemra Helps the Sickest COVID-19 Patients, Study Shows Roche's Actemra Helps the Sickest COVID-19 Patients, Study Shows
Roche's Actemra helped the sickest COVID-19 patients in a 303-patient study, the trial's lead investigator said on Thursday, bolstering what has been mixed evidence that the arthritis drug can be repurposed to help in the pandemic.Reuters Health Information (Source: Medscape Critical Care Headlines)
Source: Medscape Critical Care Headlines - November 23, 2020 Category: Intensive Care Tags: Infectious Diseases News Source Type: news

Tocilizumab: Arthritis drug may treat severe Covid
Early signs suggest it may help patients with severe breathing difficulties who are on ventilators. (Source: BBC News | Health | UK Edition)
Source: BBC News | Health | UK Edition - November 19, 2020 Category: Consumer Health News Source Type: news

Arthritis drug tocilizumab can help critically-ill Covid patients recover, trial finds
Patients given the drug in the REMAP-CAP trial, led by Imperial College London, were 87 per cent more likely to see their illness improve than those not given the drug. (Source: the Mail online | Health)
Source: the Mail online | Health - November 19, 2020 Category: Consumer Health News Source Type: news

Tocilizumab Stumbles as COVID-19 Treatment, Narrow Role Possible Tocilizumab Stumbles as COVID-19 Treatment, Narrow Role Possible
New randomized controlled trial data show tocilizumab has a narrow role at best for treating COVID-19.Medscape Medical News (Source: Medscape Infectious Diseases Headlines)
Source: Medscape Infectious Diseases Headlines - October 28, 2020 Category: Infectious Diseases Tags: Infectious Diseases News Source Type: news

Drug vignettes: Tocilizumab, CEBM (Updated 26th October 2020)
Patients with severe COVID-19 can develop cytokine release syndrome ( “cytokine storm”) and are 2 External 0 0 0 reported false https://www.medrxiv.org/content/10.1101/2020.03.01.20029769v2.full.pdf true false%> to have high circulating IL-6 concentrations. Tocilizumab is a recombinant humanized anti-human IgG1 monoclonal antibody directed against the interleukin-6 receptor (IL-6R). It has therefore been proposed to be of value in the management of severe COVID-19. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - October 28, 2020 Category: Consumer Health News Source Type: news

Oct 23 2020 This Week in Cardiology Oct 23 2020 This Week in Cardiology
COVID, tocilizumab, hypertrophic cardiomyopathy, cerebral microbleeds, and surrogate endpoints are the topics discussed by John Mandrola, MD, in this week ’ s podcasttheheart.org on Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - October 23, 2020 Category: Consumer Health News Tags: Cardiology Commentary Source Type: news

Findings Conflicted for Benefit of Tocilizumab in COVID - 19
One trial shows reduction in mortality, but no evidence of efficacy seen in two additional trials (Source: Pulmonary Medicine News - Doctors Lounge)
Source: Pulmonary Medicine News - Doctors Lounge - October 23, 2020 Category: Respiratory Medicine Tags: Infections, Internal Medicine, Critical Care, Nursing, Pharmacy, Pulmonology, Rheumatology, Journal, Source Type: news

Findings Conflicted for Benefit of Tocilizumab in COVID-19
FRIDAY, Oct. 23, 2020 -- Tocilizumab may be beneficial for adults with COVID-19 admitted to the intensive care unit (ICU), although other findings are conflicting, according to three studies and an editorial published online Oct. 20 in JAMA Internal... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - October 23, 2020 Category: Pharmaceuticals Source Type: news

Tocilizumab Does Not Prevent Intubation, Death in COVID - 19
Intubation or death, disease worsening similar for tocilizumab, placebo in hospitalized patients (Source: Pulmonary Medicine News - Doctors Lounge)
Source: Pulmonary Medicine News - Doctors Lounge - October 22, 2020 Category: Respiratory Medicine Tags: Infections, Nursing, Pharmacy, Pulmonology, Critical Care, Emergency Medicine, Journal, Source Type: news

Tocilizumab Does Not Prevent Intubation, Death in COVID-19
THURSDAY, Oct. 22, 2020 -- For moderately ill hospitalized patients with COVID-19, tocilizumab is not effective for preventing intubation or death, according to a study published online Oct. 21 in the New England Journal of Medicine. John H. Stone,... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - October 22, 2020 Category: Pharmaceuticals Source Type: news

Study finds tocilizumab improves survival in critically ill patients with COVID-19
Researchers from 68 sites across the country, led by David E. Leaf, MD, MMSc and Shruti Gupta, MD, MPH from the Division of Renal Medicine at Brigham and Women's Hospital, have investigated the effects of the anti-inflammatory drug tocilizumab on critically ill patients with laboratory-confirmed COVID-19. Unlike steroids, which suppress the immune system more broadly, tocilizumab specifically inhibits the receptor for the pro-inflammatory cytokine, IL-6. (Source: World Pharma News)
Source: World Pharma News - October 21, 2020 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Tocilizumab doesn't ease symptoms or prevent death in moderately ill COVID-19 inpatients
(Massachusetts General Hospital) The drug tocilizumab (Actemra) does not reduce the need for breathing assistance with mechanical ventilation or prevent death in moderately ill hospitalized patients with COVID-19, according to a study by researchers at Massachusetts General Hospital. The study, published in the New England Journal of Medicine, casts doubt on earlier research suggesting that tocilizumab, which is commonly prescribed for rheumatoid arthritis and other conditions, might be an effective treatment for patients with worsening cases of COVID-19. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - October 21, 2020 Category: Infectious Diseases Source Type: news

New results from a once-promising therapy show the difficulty of treating covid-19
The drug, tocilizumab, showed early potential but evidence since then has been conflicting. (Source: Washington Post: To Your Health)
Source: Washington Post: To Your Health - October 20, 2020 Category: Consumer Health News Authors: Ben Guarino Source Type: news

Study: Tocilizumab reduces risk for death in hospitalized patients with severe COVID-19
Treatment with the rheumatoid arthritis drug tocilizumab, sold as Actemra, reduces risk for death among hospitalized patients with severe COVID-19 by about 30%, a study published Tuesday by JAMA Internal Medicine found. (Source: Health News - UPI.com)
Source: Health News - UPI.com - October 20, 2020 Category: Consumer Health News Source Type: news

Efficacy of Tocilizumab in Patients With COVID-19 ARDS Efficacy of Tocilizumab in Patients With COVID-19 ARDS
How effective is tocilizumab therapy in patients who develop severe COVID-related ARDS?Critical Care (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - October 20, 2020 Category: Consumer Health News Tags: Critical Care Journal Article Source Type: news

Tocilizumab vs standard care on preventing worsening in patients hospitalized with COVID-19 pneumonia
(JAMA Network) Researchers in this randomized clinical trial compared the effect of early administration of tocilizumab with standard therapy in preventing clinical worsening in patients hospitalized with COVID-19 pneumonia. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - October 20, 2020 Category: Infectious Diseases Source Type: news

Effect of tocilizumab in adults hospitalized with COVID-19 with moderate or severe pneumonia
(JAMA Network) This randomized clinical trial assessed whether tocilizumab improves outcomes of patients hospitalized with moderate-to-severe COVID-19 pneumonia compared to usual care. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - October 20, 2020 Category: Infectious Diseases Source Type: news

Study finds tocilizumab improves survival in critically ill patients with COVID-19
(Brigham and Women's Hospital) The investigators found that when tocilizumab was administered within the first two days of intensive care unit (ICU) admission, there was a 30 percent relative decrease (and a 10 percent absolute decrease) in mortality compared to patients whose treatment did not include early use of tocilizumab. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - October 20, 2020 Category: Infectious Diseases Source Type: news

Examining association between early treatment with tocilizumab, risk of death among critically ill COVID-19 patients
(JAMA Network) Whether treatment with tocilizumab in the first two days after being admitted to an intensive care unit was associated with a reduced risk of death among critically ill patients with COVID-19 was investigated in this study. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - October 20, 2020 Category: Infectious Diseases Source Type: news

SIMPONI ARIA ® (golimumab) Approved by the U.S. Food and Drug Administration for Active Polyarticular Juvenile Idiopathic Arthritis and Extension of Its Active Psoriatic Arthritis Indication in Patients 2 Years of Age and Older
HORSHAM, PA, September 30, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has approved SIMPONI ARIA® (golimumab) for patients 2 years of age and older for the treatment of active pJIA and has extended the PsA indication for this same patient population. “This latest FDA approval of SIMPONI ARIA for pediatric use in active pJIA and active PsA not only brings a new option to young patients living with these diseases but also adds to the growing body of evidence for this treatment,” said Mathai Mammen, M.D., Ph.D., Glo...
Source: Johnson and Johnson - September 30, 2020 Category: Pharmaceuticals Source Type: news

Government looks to review Tocilizumab inclusion for treatment, again
​​Tocilizumab,a rheumatoid arthritis drug, is part of the health ministry’s clinical management protocol for Covid-19 under investigational therapies for patients with moderate symptoms of the illness. (Source: The Economic Times)
Source: The Economic Times - September 23, 2020 Category: Consumer Health News Source Type: news

Groundbreaking Covid study with Hispanics, Blacks, Native Americans shows varied results with Genentech drug
The 389-person clinical trial, which used the rheumatoid arthritis drug Actemra in patients with Covid-associated pneumonia, is part of a "call to action" for more-inclusive drug studies. (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - September 18, 2020 Category: Pharmaceuticals Authors: Ron Leuty Source Type: news

Groundbreaking Covid study with Hispanics, Blacks, Native Americans shows varied results with Genentech drug
The 389-person clinical trial, which used the rheumatoid arthritis drug Actemra in patients with Covid-associated pneumonia, is part of a "call to action" for more-inclusive drug studies. (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - September 18, 2020 Category: Biotechnology Authors: Ron Leuty Source Type: news

Roche ’s phase III EMPACTA study showed Actemra/RoActemra reduced the likelihood of needing mechanical ventilation in hospitalised patients with COVID-19 associated pneumonia
Basel, 18 September 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the phase III EMPACTA study met its primary endpoint, showing that patients with COVID-19 associated pneumonia who received Actemra ®/RoActemra® (tocilizumab) plus standard of care were 44% less likely to progress to mechanical ventilation or death compared to patients who received placebo plus standard of care (log-rank p-value = 0.0348; HR [95% CI] = 0.56 [0.32, 0.97]). The cumulative proportion of patients who progressed to mechanical ventilation or death by day 28 was 12.2% in the Actemra/RoActemra arm versus 19.3% in the placebo...
Source: Roche Media News - September 18, 2020 Category: Pharmaceuticals Source Type: news

Roche ’s phase III EMPACTA study showed Actemra/RoActemra reduced the likelihood of needing mechanical ventilation in hospitalised patients with COVID-19 associated pneumonia
Basel, 18 September 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the phase III EMPACTA study met its primary endpoint, showing that patients with COVID-19 associated pneumonia who received Actemra ®/RoActemra® (tocilizumab) plus standard of care were 44% less likely to progress to mechanical ventilation or death compared to patients who received placebo plus standard of care (log-rank p-value = 0.0348; HR [95% CI] = 0.56 [0.32, 0.97]). The cumulative proportion of patients who progressed to mechanical ventilation or death by day 28 was 12.2% in the Actemra/RoActemra arm versus 19.3% in the placebo...
Source: Roche Investor Update - September 18, 2020 Category: Pharmaceuticals Source Type: news